Navigation Links
Medicare beneficiaries substantially more likely to use brand-name drugs than VA patients

PITTSBURGH, June 10, 2013 Medicare beneficiaries with diabetes are two to three times more likely to use expensive brand-name drugs than a comparable group of patients treated within the VA Healthcare System, according to a nationwide study by researchers from the University of Pittsburgh, VA Pittsburgh Healthcare System and Dartmouth College.

Spending in Medicare Part D would have been an estimated $1.4 billion less in 2008 if brand-name and generic drug use matched that of the VA for the medications studied. The report, the first large-scale comparison of prescription drug use between Medicare Part D and the VA, is online and will be published in the print edition of the Annals of Internal Medicine on July 16.

"Our study shows that we can make a big dent in Medicare spending simply by changing the kinds of medications people are using and physicians are prescribing without worrying about whether the government should or should not negotiate drug prices," said lead author Walid Gellad, M.D., M.P.H., an assistant professor in the Pitt Graduate School of Public Health's Department of Health Policy and Management and Pitt's School of Medicine. "The levels of generic use found in the VA are attainable, and they are compatible with high quality care."

The study was jointly funded by the VA, National Institutes of Health (NIH) and Robert Wood Johnson Foundation.

Dr. Gellad and his colleagues analyzed 2008 data for over 1 million Medicare beneficiaries and 500,000 veterans to compare prescription use between Medicare and the VA, focusing on diabetes, cholesterol and blood pressure medications.

Medicare and the VA have a significantly different approach to drug prescribing. Medicare contracts with more than 1,000 private insurance companies, each using a distinct formulary and cost-sharing arrangement for prescribing drugs. The VA uses a single formulary and all veterans have the same cost-sharing arrangement.

Brand-name drugs cost considerably more than generic medications because the distributors of generics generally are not paying the cost of drug development, brand protection and marketing. In a chronic condition like diabetes, there is a broad range of available therapies with widely diverging costs, some of which can be lessened by using a generic medication rather than its brand-name counterpart.

Of the four medication groups commonly used by patients with diabetes, the researchers found that Medicare beneficiaries were more than twice as likely as VA patients to use brand-name drugs in almost every region of the country.

"We're not suggesting that Medicare turn into a VA system, nor do we believe that brand-name drugs have no role in improving health," said Dr. Gellad, also a primary care physician. "This study is about how we can manage our limited resources while maintaining high quality care. The VA shows us that it can be done for prescription drugs. Going forward, we need to understand whether these differences in prescription use have changed, if at all, from 2008 to present."


Contact: Cyndy McGrath
University of Pittsburgh Schools of the Health Sciences

Related medicine news :

1. Parker Waichman LLC Applauds Seniors for their Role in Helping to Recover $14.9 billion in Medicare Fraud over the Past Four Years
2. Skipping Meds May Raise Odds of ER Visits for Certain Medicare Patients
3. June 6 Webinar Offers Winning Medicare Advantage Go-to-Market Strategies for 2014
4. Vein Specialties Now Accepting Medicare Patients
5. Private insurers Medicare Advantage plans cost Medicare an extra $34.1 billion in 2012
6. Government Data on Extreme Medicare Health Care Price Discrepancies Only Part of the Picture for Most Americans
7. Proposed Medicare Essential plan estimated to save $180 billion over 10 years
8. Aeroflow Healthcare, Inc. Wins 456 Medicare Competitive Bids; Now Looking at Subcontractors
9. Hospitals measure up for Medicare reimbursement
10. 1 in 4 colonoscopies in Medicare patients found to be potentially inappropriate
11. Medicare Spending Not Linked to Longer Cancer Survival
Post Your Comments:
(Date:6/24/2016)... MIAMI, Fla. (PRWEB) , ... June 24, 2016 , ... ... Florida Trend magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this ... of Florida. , Seven Greenberg Traurig Shareholders received special honors as members of this ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, CA is excited ... To Recovery® program to drive cancer patients to and from their cancer treatments. ... highest quality of life and ongoing independence. Getting to and from medical treatments ...
(Date:6/24/2016)... Plano, TX (PRWEB) , ... June 24, 2016 , ... ... taking part in Genome magazine’s Code Talker Award, an essay contest in which patients ... for an award to be presented at the 2016 National Society of Genetic Counselors ...
(Date:6/24/2016)... York, NY (PRWEB) , ... June 24, 2016 ... ... publication Haute Living, is proud to recognize Dr. Barry M. Weintraub as a ... that “the most beautiful women in the world, and the most handsome men, ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... actively feeding the Frederick area economy by obtaining investment capital for emerging technology ... past 2½ years that have already resulted in more than a million dollars ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... announced the establishment of Astellas Farma Colombia (AFC), a new affiliate with operations headquartered in Bogota. Colombia ... ... ... ... Astellas is a pharmaceutical ...
(Date:6/23/2016)... , June 23, 2016 The vast majority ... outpatient dialysis facility.  Treatments are usually 3 times a ... per visit, including travel time, equipment preparation and wait ... but especially grueling for patients who are elderly and ... skilled nursing and rehabilitation centers for some duration of ...
(Date:6/23/2016)... YORK , June 23, 2016 ... waters, but it continues to present great opportunities to ... companies for today: Intrexon Corp. (NYSE: XON ... Arena Pharmaceuticals Inc. (NASDAQ: ARNA ), and ... more about these stocks and receive your complimentary trade ...
Breaking Medicine Technology: